These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 36992407)

  • 1. Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
    Lundstrom K
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy Cargoes Based on Viral Vector Delivery.
    Lundstrom K
    Curr Gene Ther; 2023; 23(2):111-134. PubMed ID: 36154608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral vectors engineered for gene therapy.
    Lundstrom K
    Int Rev Cell Mol Biol; 2023; 379():1-41. PubMed ID: 37541721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine.
    Krutzke L; Rösler R; Allmendinger E; Engler T; Wiese S; Kochanek S
    Elife; 2022 Jul; 11():. PubMed ID: 35781137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines.
    Michalik S; Siegerist F; Palankar R; Franzke K; Schindler M; Reder A; Seifert U; Cammann C; Wesche J; Steil L; Hentschker C; Gesell-Salazar M; Reisinger E; Beer M; Endlich N; Greinacher A; Völker U
    Haematologica; 2022 Apr; 107(4):947-957. PubMed ID: 35045692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virus therapy: A new era of cancer treatment at dawn.
    Fukuhara H; Ino Y; Todo T
    Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New viral vectors for infectious diseases and cancer.
    Sasso E; D'Alise AM; Zambrano N; Scarselli E; Folgori A; Nicosia A
    Semin Immunol; 2020 Aug; 50():101430. PubMed ID: 33262065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
    Custers J; Kim D; Leyssen M; Gurwith M; Tomaka F; Robertson J; Heijnen E; Condit R; Shukarev G; Heerwegh D; van Heesbeen R; Schuitemaker H; Douoguih M; Evans E; Smith ER; Chen RT;
    Vaccine; 2021 May; 39(22):3081-3101. PubMed ID: 33676782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-replicating vehicles based on negative strand RNA viruses.
    Lundstrom K
    Cancer Gene Ther; 2023 Jun; 30(6):771-784. PubMed ID: 35169298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering HSV-1 Vectors for Gene Therapy.
    Goins WF; Huang S; Hall B; Marzulli M; Cohen JB; Glorioso JC
    Methods Mol Biol; 2020; 2060():73-90. PubMed ID: 31617173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
    Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
    Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential mechanisms of vaccine-induced thrombosis.
    Marietta M; Coluccio V; Luppi M
    Eur J Intern Med; 2022 Nov; 105():1-7. PubMed ID: 35953336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Viruses for the Treatment of Metastatic Melanoma.
    Trager MH; Geskin LJ; Saenger YM
    Curr Treat Options Oncol; 2020 Mar; 21(4):26. PubMed ID: 32266483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
    Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Immunol; 2022; 13():956825. PubMed ID: 36177033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data.
    Cari L; Alhosseini MN; Fiore P; Pierno S; Pacor S; Bergamo A; Sava G; Nocentini G
    J Autoimmun; 2021 Dec; 125():102742. PubMed ID: 34710832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alphaviruses in cancer immunotherapy.
    Lundstrom K
    Int Rev Cell Mol Biol; 2023; 379():143-168. PubMed ID: 37541722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
    Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
    Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer.
    Lundstrom K
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Folegatti PM; Jenkin D; Morris S; Gilbert S; Kim D; Robertson JS; Smith ER; Martin E; Gurwith M; Chen RT;
    Vaccine; 2022 Aug; 40(35):5248-5262. PubMed ID: 35715352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral-mediated gene transfer for cancer treatment.
    Wilson DR
    Curr Pharm Biotechnol; 2002 Jun; 3(2):151-64. PubMed ID: 12022258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.